Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CBFB | Q13951 | 2/20 | 0.31 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.31 |
| ▸ | TUBB | P07437 | 1/20 | 0.31 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.31 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.31 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.31 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL844656 | 1.00 | MAP2K1 (0.45) | MAP2K1S1PR1S1PR3ESR1MEN1 | |
| SCHEMBL30536472 | 1.00 | MAP2K1 (0.45) | MAP2K1S1PR1S1PR3ESR1MEN1 | |
| SCHEMBL21526761 | 1.00 | MAP2K1 (0.45) | MAP2K1S1PR1S1PR3ESR1MEN1 | |
| SCHEMBL844785 | 1.00 | MAP2K1 (0.45) | MAP2K1S1PR1S1PR3ESR1MEN1 | |
| SCHEMBL13765315 | 0.94 | MAP2K1 (0.45) | MAP2K1S1PR1S1PR3ESR1MAPK1 | |
| SCHEMBL13950576 | 0.94 | MAP2K1 (0.45) | MAP2K1S1PR1S1PR3ESR1MAPK1 | |
| SCHEMBL29055719 | 0.92 | MAP2K1 (0.49) | MAP2K1S1PR1S1PR3ESR1MEN1 | |
| SCHEMBL30536457 | 0.92 | MAP2K1 (0.49) | MAP2K1S1PR1S1PR3ESR1MEN1 | |
| SCHEMBL844132 | 0.92 | MAP2K1 (0.49) | MAP2K1S1PR1S1PR3ESR1MEN1 | |
| SCHEMBL844212 | 0.92 | MAP2K1 (0.49) | MAP2K1S1PR1S1PR3ESR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188276-B1 | SUBSTITUTED HYDANTOINS | HOFFMANN LA ROCHE (CH) | 2012-03-28 | — | — | EP | claimed |
| US-7557221-B2 | Substituted hydantoins | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | claimed |
| US-20090048452-A1 | (R)-5-[4-(2-Hydroxy-ethoxy)-phenyl]-3-[(S)-1-(6-iodo-1H-benzoimidazol-2-yl)-2-phenyl-ethyl]-imidazolidine-2,4-dione; map kinase inhibitors; antihyperproliferative agents | CHEN SHAOQING | 2009-02-19 | — | — | US | claimed |
| US-20220105180-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| US-10946093-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | GENENTECH, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10646567-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | GENENTECH, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3563870-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2019-11-06 | — | — | EP | disclosed |
| EP-3169361-B1 | COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | disclosed |
| EP-2739358-B1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2018-11-28 | — | — | EP | disclosed |
| US-20180021431-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9724413-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | GENENTECH, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3169361-A1 | COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2017-05-24 | — | — | EP | disclosed |
| US-20170112925-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | GENENTECH, INC. (US) | 2017-04-27 | — | — | US | disclosed |
| WO-2016011160-A1 | COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | GENENTECH, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20140341902-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | GENENTECH, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2188276-B1 | SUBSTITUTED HYDANTOINS | HOFFMANN LA ROCHE (CH) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10946093-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | CD274, PDCD1, PDCD1LG2 | MAP2K1 13/4885S1PR1 913/4885S1PR3 1282/4885 |
| US-20090048452-A1 | (R)-5-[4-(2-Hydroxy-ethoxy)-phenyl]-3-[(S)-1-(6-iodo-1H-benzoimidazol-2-yl)-2-phenyl-ethyl]-imidazolidine-2,4-dione; map kinase inhibitors; antihyperproliferative agents | MAPK1, MAP3K2, MAP3K1 | MAP2K1 35/4885S1PR1 1177/4885S1PR3 1360/4885 |
| US-10646567-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | CD274, PDCD1, PDCD1LG2 | MAP2K1 13/4885S1PR1 913/4885S1PR3 1282/4885 |
| US-20180021431-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | CD274, PDCD1, PDCD1LG2 | MAP2K1 13/4885S1PR1 913/4885S1PR3 1282/4885 |
| US-20140341902-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | CD274, PDCD1, PDCD1LG2 | MAP2K1 13/4885S1PR1 913/4885S1PR3 1282/4885 |
| US-20170112925-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | CD274, PDCD1, PDCD1LG2 | MAP2K1 13/4885S1PR1 913/4885S1PR3 1282/4885 |
| US-20220105180-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | CD274, PDCD1, PDCD1LG2 | MAP2K1 13/4885S1PR1 913/4885S1PR3 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.